用于治疗恰加斯病患者的苄硝唑最新情况。
An update on benznidazole for the treatment of patients with Chagas disease.
作者信息
Thakare R, Dasgupta A, Chopra S
机构信息
Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
出版信息
Drugs Today (Barc). 2018 Jan;54(1):15-23. doi: 10.1358/dot.2018.54.1.2753402.
Chagas disease is a vector-borne, systemic and chronic parasitic infection caused by Trypanosoma cruzi with approximately 8 million cases worldwide. The treatment for acute phase of Chagas disease consists of benznidazole and nifurtimox, although this treatment combination falls short in terms of efficacy against chronic phases of infection. This review provides an update on benznidazole progress and approval by the U.S. Food and Drug Administration in 2017 for the treatment of Chagas disease along with its lacunae.
恰加斯病是一种由克氏锥虫引起的经媒介传播的全身性慢性寄生虫感染，全球约有800万病例。恰加斯病急性期的治疗药物包括苯硝唑和硝呋莫司，不过这种联合治疗在对抗慢性感染阶段的疗效方面存在不足。本综述介绍了苯硝唑的研究进展以及2017年美国食品药品监督管理局对其治疗恰加斯病的批准情况，并指出了其不足之处。
Zotero 插件